Andrew Ruplin, PharmD, clinical instructor and oncology clinical pharmacist at Seattle Cancer Care Alliance and the University of Washington in Seattle, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss new drug approvals for metastatic castration-sensitive prostate cancer. Astellas and Pfizer Inc. provided support for this podcast episode through an educational grant.
Music Credit: "Fireflies and Stardust" by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by May 7, 2023. The planners and faculty for this episode have no conflicts to disclose, and the episode has no commercial support. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center’s Commission on Accreditation.
Check out these resources from today’s episode:
To discuss the information in this episode with other oncology nurses, visit the ONS Communities.
To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
Listen on Apple Podcasts, Listen on Google Podcasts, Listen on Stitcher, Listen on Spotify, Listen on Amazon Music
Expand your knowledge by listening to the Oncology Nursing Podcast.View All Podcasts